Advanced Enzyme Technologies Ltd
Advanced Enzyme Technologies Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company aims to maintain a mid-teen percentage growth rate over the longer term, as stated by Mukund Kabra. The company aims to maintain mid-teen percentage revenue growth over the long term, despite current uncertainties globally (Page 15, 21).
From Advanced Enzyme Technologies Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- The company aims to maintain a mid-teen percentage growth rate over the longer term, as stated by Mukund Kabra.
- Growth is expected from both existing and new products, supported by increased R&D efforts and an upcoming larger R&D center.
- Expansion into new geographies beyond baking, including food, pharma, and bioprocessing sectors, is planned.
- Continued focus on multiple product categories: animal nutrition, human nutrition, biocatalysts, probiotics, and others.
- The company sees significant headroom for growth, currently holding less than 2% global market share.
- Tariff-related uncertainties remain but strategies are in place to mitigate their impact.
2 more points from Advanced Enzyme Technologies Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Advanced Enzyme Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is investing in a new R&D center expected to come on stream next year, which will substantially increase R&D spending by INR 10-12 crores compared to FY26, with gradual ramp-up thereafter.
- Planned capitalization of some R&D assets by the end of this fiscal year, partially becoming active.
- Expansion and capacity utilization increasing in the specialized manufacturing subsidiary, leading to higher depreciation expenses, though margins remain low (8-10%).
- The company is actively exploring ways to mitigate tariff impacts, including changing sourcing and value addition locations.
2 more points from Advanced Enzyme Technologies Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Advanced Enzyme Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Advanced Enzyme Technologies Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Advanced Enzyme Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹203 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Advanced Enzyme Technologies Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Arthneeti Pro · Annual
Advanced Enzyme Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Advanced Enzyme Technologies Ltd Q2 FY26 results?
The company aims to maintain a mid-teen percentage growth rate over the longer term, as stated by Mukund Kabra. The company aims to maintain mid-teen percentage revenue growth over the long term, despite current uncertainties globally (Page 15, 21).
What is Advanced Enzyme Technologies Ltd share price analysis?
Advanced Enzyme Technologies Ltd currently shows a neutral. The stock trades at a P/E of 19.0 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.
Is Advanced Enzyme Technologies Ltd planning capital expenditure?
The company is investing in a new R&D center expected to come on stream next year, which will substantially increase R&D spending by INR 10-12 crores compared to FY26, with gradual ramp-up thereafter.
Keep Advanced Enzyme Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.